BioInvent Financial Statement 1 January – 31 December 2014

Regulatory News:

BioInvent International AB (STO:BINV)

Fourth quarter 2014, October – December

· Net sales for October – December 2014 amounted to SEK 1.7 (50) million.

· Earnings after tax for October – December 2014: SEK -28 (20) million.

· Earnings after tax per share for October – December before and after dilution: SEK -0.25 (0.24).

· Cash flow from current operations and investment activities for October – December 2014: SEK -25 (25) million.

Full year report 2014, January – December

· Net sales for January – December 2014 amounted to SEK 47 (82) million.

· Earnings after tax for January – December 2014: SEK -54 (-18) million.

· Earnings after tax per share for January – December before and after dilution: SEK -0.53 (-0.23).

· Liquid funds as of 31 December 2014: SEK 46 (65) million. Cash flow from current operations and investment activities for January – December 2014: SEK -76 (-55) million.

Important events in the fourth quarter and after the reporting period

· BioInvent announced in January that the antibody BI-1206 will advance to a Phase I/II trial with full funding by Cancer Research UK, CRT and LLR.

· BioInvent announced in January that Anna Wickenberg was appointed as Head of Clinical Development.

Comments from the CEO ”Cancer Research UK's decision to conduct a phase I/II study with BI-1206, on behalf of BioInvent, represents a value of more than SEK 60 million to BioInvent. Their decision to initiate clinical trials of BI-1206 is based on the convincing preclinical documentation we have developed for the antibody and which we intend to publish in a highly ranked scientific journal.

Our aim is to start additional important clinical studies for other antibodies in 2015, based on funding models similar to the one agreed with CRUK. This means significant cost savings for BioInvent whilst preserving the value of the projects and gaining access to a network of leading clinicians.

This year we will invest a large portion of our preclinical resources in the T-reg and TAM programs, where our platform F.I.R.S.T.™ is an "engine" to develop novel immuno oncology drugs. These broad programs are important components of our ongoing business development efforts and we see good opportunities in 2015 to create licensing deals where BioInvent retains significant strategic value in the programs.

I see a unique opportunity in progressing our products in clinical trials in orphan indications, where we have a possibility to create patient benefits compared to current standard of care, and hence create significant value through multiple clinical milestones in the coming years.", said Michael Oredsson, CEO of BioInvent.

Contact

Any questions regarding this report will be answered by Michael Oredsson, CEO, phone.+46 (0)46 286 85 67, mobile +46 (0)707 18 89 30. The report is also available at www.bioinvent.com

BioInvent International AB, listed on the NASDAQ Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of new drugs, and provide BioInvent with the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, and Xoma.

Information disclosed in this financial statement is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 18 February, 2015.

This information was brought to you by Cision http://news.cision.com